Impaired kidney function was also identified as a key risk factor for heart disease, contributing to about 12% of global ...

In the field of paediatrics, the concept of normal (ie, typical)—in contrast to different, special, deviant, delayed, or ...

The daily living and mobility components will be under review, but there are no plans to means-test the benefit.

Chronic Kidney Disease affects 14% of adults and caused 1.5M deaths in 2023—a 6% rise since 1993. Often underdiagnosed, it drives heart disease and disability. Experts call for early detection, access ...

Benefit rules shift with quiet consequences for households already stretched. Fresh guidance will shape reviews, payments and ...

A child's healthy growth is a complex interplay of genetics, hormones and nutrition. Experts emphasize that factors like ...

The UK Government said it has launched the Timms Review to ensure that Personal Independence Payment (PIP) is “fair and fit for the future in a changing world” and aims to help support disabled people ...

Behind the headlines, benefit award lengths can stretch or shrink in ways many people don’t expect when they first apply.

Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA ...

BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.